XI3.F BIOCELTIX S.A. ZY -10

Healthcare Biotechnology Frankfurt Exchange
20.40 EUR
Close of Oct 12, 2026
13.98 27.10
Market cap
EUR 113M
P/E
-
P/B
7.95x
ROE
-34.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is XI3.F undervalued?

Graham number

The Graham number of BIOCELTIX S.A. ZY -10 cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

BIOCELTIX S.A. ZY -10 fundamental analysis

No fundamental analysis for BIOCELTIX S.A. ZY -10 yet.

BIOCELTIX S.A. ZY -10 stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About BIOCELTIX S.A. ZY -10

Bioceltix S.A. engages in the development of veterinary biologics based on mesenchymal stem cells. The company's products include BCX-CM-J, a stem-cell based medicinal drug for the treatment of osteoarthritis in dogs; BCX-CM-AD, an allogeneic stem cell-based medicinal product for the treatment of atopic dermatitis in dogs; and BCX-EM, an allogeneic stem cell-based medicinal product for the treatment of osteoarthritis in horses. It also develops BCX-CM-Sec, a research project…

Full company profile